Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib

@article{Venkatachalam2017CostOT,
  title={Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib},
  author={Meena Venkatachalam and David D. Stenehjem and Neehar D. Parikh and Prianka Singh and Benjamin E. Marett and Bruce E Sill and Tami Wisniewski and Prakash and P Shukla and Beata Korytowsky and M. K. Siddiqui},
  journal={Value in Health},
  year={2017},
  volume={20}
}
1 Citations
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
TLDR
Overall survival (OS) and progression-free survival (PFS) were evaluated for the matching-adjusted second-line CELESTIAL population and compared with those for RESORCE using weighted Kaplan-Meier curves and parametric modeling to compare the efficacy and safety of cabozantinib and regorafenib. Expand